German AMNOG reform fails to hit the mark
This article was originally published in Scrip
Executive Summary
Reform of Germany's early benefit assessments is currently under discussion, but the change floated looks unlikely to solve any of the main issues that are frustrating companies. During a recent debate in the German parliament, industry made little progress on ensuring that rebates remain confidential, and nothing is likely to change on the thorny issue of comparators, said Dr Alexander Natz, secretary general of EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs and Brussels representative for the BPI, which represents small- and medium-sized companies in Germany..